Generic of Dilantin® Chewable Tablets Launches

On December 27, 2012, Mylan received final FDA approval for the generic equivalent of Pfizer’s Dilantin® Chewable Tablets. Dilantin Infatabs® had estimated total U.S. annual sales of approximately $16.5 million for the twelve months ending September 2012, according to IMS.

Dilantin Infatabs® are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures. However, like many other seizure medications, it may also be effective for nerve pain treatment (though it is not approved for this use).